Literature DB >> 10577695

The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study.

E Steenland1, J W Leer, H van Houwelingen, W J Post, W B van den Hout, J Kievit, H de Haes, H Martijn, B Oei, E Vonk, E van der Steen-Banasik, R G Wiggenraad, J Hoogenhout, C Wárlám-Rodenhuis, G van Tienhoven, R Wanders, J Pomp, M van Reijn, I van Mierlo, E Rutten, J Leer, T van Mierlo.   

Abstract

PURPOSE: To answer the question whether a single fraction of radiotherapy that is considered more convenient to the patient is as effective as a dose of multiple fractions for palliation of painful bone metastases. PATIENTS: 1171 patients were randomised to receive either 8 Gy x 1 (n = 585) or 4 Gy x 6 (n = 586). The primary tumour was in the breast in 39% of the patients, in the prostate in 23%, in the lung in 25% and in other locations in 13%. Bone metastases were located in the spine (30%), pelvis (36%), femur (10%), ribs (8%), humerus (6%) and other sites (10%).
METHOD: Questionnaires were mailed to collect information on pain, analgesics consumption, quality of life and side effects during treatment. The main endpoint was pain measured on a pain scale from 0 (no pain at all) to 10 (worst imaginable pain). Costs per treatment schedule were estimated.
RESULTS: On average, patients participated in the study for 4 months. Median survival was 7 months. Response was defined as a decrease of at least two points as compared to the initial pain score. The difference in response between the two treatment groups proved not significant and stayed well within the margin of 10%. Overall, 71% experienced a response at some time during the first year. An analysis of repeated measures confirmed that the two treatment schedules were equivalent in terms of palliation. With regard to pain medication, quality of life and side effects no differences between the two treatment groups were found. The total number of retreatments was 188 (16%). This number was 147 (25%) in the 8 Gy x 1 irradiation group and 41 (7%) in the 4 Gy x 6 group. It was shown that the level of pain was an important reason to retreat. There were also indications that doctors were more willing to retreat patients in the single fraction group because time to retreatment was substantially shorter in this group and the preceding pain score was lower. Unexpectedly, more pathological fractures were observed in the single fraction group, but the absolute percentage was low. In a cost-analysis, the costs of the 4 Gy x 6 and the 8 Gy x 1 treatment schedules were calculated at 2305 and 1734 Euro respectively. Including the costs of retreatment reduced this 25% cost difference to only 8%. The saving of radiotherapy capacity, however, was considered the major economic advantage of the single dose schedule.
CONCLUSION: The global analysis of the Dutch study indicates the equality of a single fraction as compared to a 6 fraction treatment in patients with painful bone metastases provided that 4 times more retreatments are accepted in the single dose group. This equality is also shown in long term survivors. A more detailed analysis of the study is in progress.

Entities:  

Mesh:

Year:  1999        PMID: 10577695     DOI: 10.1016/s0167-8140(99)00110-3

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  128 in total

Review 1.  The evolving role of stereotactic radiosurgery and stereotactic radiation therapy for patients with spine tumors.

Authors:  Jack P Rock; Samuel Ryu; Fang-Fang Yin; Faye Schreiber; Muwaffak Abdulhak
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

2.  The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery.

Authors:  Yoshiya Yamada; Evangelia Katsoulakis; Ilya Laufer; Michael Lovelock; Ori Barzilai; Lily A McLaughlin; Zhigang Zhang; Adam M Schmitt; Daniel S Higginson; Eric Lis; Michael J Zelefsky; James Mechalakos; Mark H Bilsky
Journal:  Neurosurg Focus       Date:  2017-01       Impact factor: 4.047

Review 3.  Malignant bone pain: pathophysiology and treatments.

Authors:  C Ripamonti; F Fulfaro
Journal:  Curr Rev Pain       Date:  2000

Review 4.  Palliative radiotherapy for bone metastases from lung cancer: Evidence-based medicine?

Authors:  Alysa Fairchild
Journal:  World J Clin Oncol       Date:  2014-12-10

5.  Taking into account the impact of attrition on the assessment of response shift and true change: a multigroup structural equation modeling approach.

Authors:  Mathilde G E Verdam; Frans J Oort; Yvette M van der Linden; Mirjam A G Sprangers
Journal:  Qual Life Res       Date:  2014-10-18       Impact factor: 4.147

Review 6.  The role of radiation therapy in the treatment of metastatic castrate-resistant prostate cancer.

Authors:  Jim N Rose; Juanita M Crook
Journal:  Ther Adv Urol       Date:  2015-06

7.  Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases.

Authors:  Karl-Ake Jansson; Henrik C F Bauer
Journal:  Eur Spine J       Date:  2005-03-03       Impact factor: 3.134

8.  Reply to Serin et al.

Authors:  David Li; Holly G Prigerson; Josephine Kang; Paul K Maciejewski
Journal:  J Pain Symptom Manage       Date:  2017-04-22       Impact factor: 3.612

9.  Considerations for Quality Improvement in Radiation Oncology Therapy for Patients with Uncomplicated Painful Bone Metastases.

Authors:  Anne M Walling; Phillip J Beron; Tania Kaprealian; Patrick A Kupelian; Neil S Wenger; Susan A McCloskey; Christopher R King; Michael Steinberg
Journal:  J Palliat Med       Date:  2017-02-23       Impact factor: 2.947

10.  Percutaneous image-guided cryoablation of painful metastases involving bone: multicenter trial.

Authors:  Matthew R Callstrom; Damian E Dupuy; Stephen B Solomon; Robert A Beres; Peter J Littrup; Kirkland W Davis; Ricardo Paz-Fumagalli; Cheryl Hoffman; Thomas D Atwell; J William Charboneau; Grant D Schmit; Matthew P Goetz; Joseph Rubin; Kathy J Brown; Paul J Novotny; Jeff A Sloan
Journal:  Cancer       Date:  2012-10-12       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.